Primary thromboprophylaxis with heparins for arteriovenous fistula failure in pediatric patients

Journal of Vascular Access

Volumn 8, Issue 4, 2007, Pages 235-244

  Sharathkumar, Anjali ^a   Hirschl, R ^a   Pipe, S ^a   Crandell, C ^a   Adams, B ^a   Lin, J J ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Arteriovenous fistula (AVF); Child; Hemodialysis; Low molecular weight heparin(LMWH)

Indexed keywords

ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 10A; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ADOLESCENT; ADULT; ARTERIOVENOUS FISTULA; ARTICLE; BLEEDING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG WITHDRAWAL; GRAFT FAILURE; GRAFT SURVIVAL; HEMATOMA; HEMODIALYSIS; HUMAN; INCIDENCE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; OUTCOME ASSESSMENT; PATIENT MONITORING; SCHOOL CHILD; STENOSIS; THROMBECTOMY; THROMBOCYTOPENIA; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT OUTCOME;

EID: 39449083248     PISSN: 11297298     EISSN: None     Source Type: Journal    
DOI: 10.1177/112972980700800404     Document Type: Article

References (56)

1. III. NKF-K/DOQI Clinical Practice Guidelines for Vascular Access: update 2000. Am J Kidney Dis 2001; 37: S137-S181.
2. Ethier JH, Lindsay RM, Barre PE, Kappel JE, Carlisle EJ, Common A. Clinical practice guidelines for vascular access. Canadian Society of Nephrology. J Am Soc Nephrol 1999; 10 (Suppl 13): S297-S305.
3. Dhingra RK, Young EW, Hulbert-Shearon TE, Leavey SF, Port FK. Type of vascular access and mortality in U.S. hemodialysis patients. Kidney Int 2001; 60: 1443-51.
4. Lee H, Manns B, Taub K, et al. Cost analysis of ongoing care of patients with end-stage renal disease:the impact of dialysis modality and dialysis access. Am J Kidney Dis 2002; 40: 611-22.
5. Rayner HC, Besarab A, Brown WW, Disney A, Saito A, Pisoni RL. Vascular access results from the Dialysis Outcomes and Practice Patterns Study (DOPPS): performance against Kidney Disease Outcomes Quality Initiative (K/DOQI) Clinical Practice Guidelines. Am J Kidney Dis 2004; 44: 22-6.
6. Rayner HC, Pisoni RL, Bommer J, et al. Mortality and hospitalization in haemodialysis patients in five European countries: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004; 19: 108-20.
7. Chand DH, Brier M, Strife CF. Comparison of vascular access type in pediatric hemodialysis patients with respect to urea clearance, anemia management, and serum albumin concentration. Am J Kidney Dis 2005; 45: 303-8.
8. Feldman HI, Held PJ, Hutchinson JT, et al. Hemodialysis vascular access morbidity in the United States. Kidney Int 1993; 43: 1091-6.
9. Hakim R, Himmelfarb J. Hemodialysis access failure: a call to action. Kidney Int 1998; 54: 1029-40.
10. Patel NH, Revanur VK, Khanna A, et al. Vascular access for hemodialysis: an indepth review. J Nephrol 2001; 14: 532.
11. Robbin ML, Chamberlain NE, Lockhart ME, et al. Hemodialysis arteriovenous fistula maturity: US evaluation. Radiology 2002; 225: 59-64.
12. Bourquelot P, Gagnadoux MF. Vascular access for hemodialysis in children. Pediatr Nephrol 1997; 11: 659-60.
13. Kreidy R, Ghabril R. Arteriovenous fistula for chronic hemodialysis in children. J Med Liban 2000; 48: 288-93.
14. Lumsden AB, MacDonald MJ, Allen RC, Dodson TF. Hemodialysis access in the pediatric patient population. Am J Surg 1994; 168: 197-201.
15. Ramage IJ, Bailie A, Tyerman KS, McColl JH, Pollard SG, Fitzpatrick MM. Vascular access survival in children and young adults receiving long-term hemodialysis. Am J Kidney Dis 2005; 45: 708-14.
16. Sheth RD, Brandt ML, Brewer ED, Nuchtern JG, Kale AS, Goldstein SL. Permanent hemodialysis vascular access survival in children and adolescents with end-stage renal disease. Kidney Int 2002; 62: 1864-9.
17. Sanabia J, Polo JR, Morales MD, Canals MJ, Polo J, Serantes A. Microsurgery in gaining paediatric vascular access for haemodialysis. Microsurgery 1993; 14: 276-9.
18. Erdem Y, Haznedaroglu IC, Celik I, et al. Coagulation, fibrinolysis and fibrinolysis inhibitors in haemodialysis patients: contribution of arteriovenous fistula. Nephrol Dial Transplant 1996; 11: 1299-305.
19. Kowalewski R, Zimnoch L, Wojtukiewicz MZ, et al. Coagulation activators and inhibitors in the neointima of polyester vascular grafts. Blood Coagul Fibrinolysis 2003; 14: 433-9.
20. Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol 2004; 24: 1015-22.
21. Chen J, Lopez JA. Interactions of platelets with subendothelium and endothelium. Microcirculation 2005; 12: 235-46.
22. Dunkley S, Harrison P. Platelet activation can occur by shear stress alone in the PFA-100 platelet analyser. Platelets 2005; 16: 81-4.
23. Fiskerstrand CE, Burne ME, Willim P, et al. Double-blind randomized trial of the effect of ticlopidine in arteriovenous fistulas for hemodialysis. Artif Organs 1985; 9: 61-3.
24. Grontoft KC, Mulec H, Gutierrez A, Olander R. Thromboprophylactic effect of ticlopidine in arteriovenous fistulas for haemodialysis. Scand J Urol Nephrol 1985; 19: 55-7.
25. Harter HR, Burch JW, Majerus PW, et al. Prevention of thrombosis in patients on hemodialysis by low-dose aspirin. N Engl J Med 1979; 301: 577-9.
26. Janicki K, Dmoszynska A, Janicka L, et al. Influence of antiplatelet drugs on occlusion of arteriovenous fistula in uraemic patients. Int Urol Nephrol 1992; 24: 83-9.
27. Grontoft KC, Larsson R, Mulec H, Weiss LG, Dickinson JP. Effects of ticlopidine in AV-fistula surgery in uremia. Fistula Study Group. Scand J Urol Nephrol 1998; 32: 276-83.
28. Kaufman JS, O'Connor TZ, Zhang JHY, et al. Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. J Am Soc Nephrol 2003; 14: 2313-21.
29. Sreedhara R, Himmelfarb J, Lazarus JM, Hakim RM. Anti-platelet therapy in graft thrombosis: results of a prospective, randomized, double-blind study. Kidney Int 1994; 45: 1477-83.
30. Harvey R, Bredenberg CE, Couper L, Himmelfarb J. Aspirin enhances platelet-derived growth factor-induced vascular smooth muscle cell proliferation. J Vasc Surg 1997; 25: 689-95.
31. Freeman RV, Mehta RH, Al BW, Cooper JV, Kline-Rogers E, Eagle KA. Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/ IIIa inhibitors. J Am Coll Cardiol 2003; 41: 718-24.
32. Yevzlin AS, Conley EL, Sanchez RJ, Young HN, Becker BN. Vascular access outcomes and medication use: a USRDS study. Semin Dial 2006; 19: 535-9.
33. Crowther MA, Clase CM, Margetts PJ, et al. Low-intensity warfarin is ineffective for the prevention of PTFE graft failure in patients on hemodialysis: a randomized controlled trial. J Am Soc Nephrol 2002; 13: 2331-7.
34. Lopez-Sanchez M, Gonzalez-Fernandez C, Valero-Diaz de LC, Dominguez-Artiga MJ, Hernandez-Hernandez MA. Enoxaparin, retroperitoneal haematoma in the elderly and impaired renal function. Anaesth Intensive Care 2005; 33: 689-90.
35. Malik A, Capling R, Bastani B. Enoxaparin-associated retroperitoneal bleeding in two patients with renal insufficiency. Pharmacotherapy 2005; 25: 769-72.
36. Remuzzi G. Bleeding in renal failure. Lancet 1988; 1: 1205-8.
37. Da Silva MS, Sobel M. Anticoagulants: to bleed or not to bleed, that is the question. Semin Vasc Surg 2002; 15: 256-67.
38. Sobel M, McNeill PM, Carlson PL, et al. Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo. J Clin Invest 1991; 87: 1787-93.
39. Bowles L, Cohen H. Inherited thrombophilias and anticoagulation in pregnancy. Best Pract Res Clin Obstet Gynaecol 2003; 17: 471-89.
40. Haas S, Wolf H, Kakkar AK et al. Prevention of fatal pulmonary embolism and mortality in surgical patients: a randomized double-blind comparison of LMWH with unfractionated heparin. Thromb Haemost 2005; 94: 814-9.
41. Hamad GG, Choban PS. Enoxaparin for thromboprophylaxis in morbidly obese patients undergoing bariatric surgery: findings of the prophylaxis against VTE outcomes in bariatric surgery patients receiving enoxaparin (PROBE) study. Obes Surg 2005; 15: 1368-74.
42. Hull RD, Schellong SM, Tapson VF, et al. Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: methodology for the EXCLAIM study. J Thromb Thrombolysis 2006; 22: 31-8.
43. Rasmussen MS, Jorgensen LN, Wille-Jorgensen P, et al. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost 2006; 4: 2384-90.
44. Deruelle P, Denervaud M, Hachulla E, et al. Use of low-molecular-weight heparin from the first trimester of pregnancy: A retrospective study of 111 consecutive pregnancies. Eur J Obstet Gynecol Reprod Biol 2006; 127: 73-8.
45. Dix D, Andrew M, Marzinotto V, et al. The use of low molecular weight heparin in pediatric patients: a prospective cohort study. J Pediatr 2000; 136: 439-45.
46. Monagle P, Chan A, Massicotte P, Chalmers E, Michelson AD. Antithrombotic therapy in children: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 645S-87S.
47. Kranz B, Vester U, Nadalin S, Paul A, Broelsch CE, Hoyer PF. Outcome after kidney transplantation in children with thrombotic risk factors. Pediatr Transplant 2006; 10: 788-93.
48. Gaspari F, Vigano G, Orisio S, Bonati M, Livio M, Remuzzi G. Aspirin prolongs bleeding time in uremia by a mechanism distinct from platelet cyclooxygenase inhibition. J Clin Invest 1987; 79: 1788-97.
49. Renal Data System, USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases.
50. Barba R, Marco J, Martin-Alvarez H, et al. The influence of extreme body weight on clinical outcome of patients with venous thromboembolism: findings from a prospective registry (RIETE). J Thromb Haemost 2005; 3: 856-62.
51. Nagge J, Crowther M, Hirsh J. Is impaired renal function a contraindication to the use of low-molecular-weight heparin? Arch Intern Med 2002; 162: 2605-9.
52. Perry SL, O'Shea SI, Byrne S, Szczech LA, Ortel TL. A multi-dose pharmacokinetic study of dalteparin in haemodialysis patients. Thromb Haemost 2006; 96: 750-5.
53. Stobe J, Siegemund A, Achenbach H, Preiss C, Preiss R. Evaluation of the pharmacokinetics of dalteparin in patients with renal insufficiency. Int J Clin Pharmacol Ther 2006; 44: 455-65.
54. Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006; 144: 673-84.
55. Sharathkumar A, Revel-Vilk S, Chan AK, Marzi-notto V, Andrew M, Massicotte MP. Outcome of children with thromboembolic events (TEs) treated with low molecular weight heparin (LMWH). J Pediatr Hematol Oncol 2003; 24: A1.
56. Overholser BR, Brophy DF, Sowinski KM. Development of an efficient sampling strategy to predict enoxaparin pharmacokinetics in stage 5 chronic kidney disease. Ther Drug Monit 2006; 28: 807-12.